Diabetic Kidney Care Redefined with a New Way into Remission

• Nour Hammad ^[2] ; Mohamed Hassanein ^[1] ; Mahboob Rahman ^[3]
  1. [1] University of Mississippi Medical Center

     University of Mississippi Medical Center

     Estados Unidos

     
  2. [2] Division of Nephrology and Hypertension, University Hospitals Cleveland Medical Center, 11100 Euclid Avenue, Cleveland, OH 44106, USA
  3. [3] Division of Nephrology and Hypertension, University Hospitals Cleveland Medical Center, 11100 Euclid Avenue, Cleveland, OH 44106, USA Louis Stokes Cleveland VA Medical Center, 10701 East Boulevard, Cleveland, OH 44106, USA Case Western Reserve University, 10900 Euclid Avenue, Cleveland, OH 44106, USA

  Mostrar afiliaciones +
• Localización: Endocrinology and metabolism clinics of North America, ISSN 0889-8529, Vol. 52, Nº. 1, 2023, págs. 101-118
• Idioma: inglés
• Texto completo no disponible (Saber más ...)
• Resumen

  • Diabetic kidney disease has been a leading cause for end-stage kidney disease. Traditional methods to slow progression include tight glycemic control, blood pressure control, and use of renin-angiotensin axis inhibitors. Finerenone and sodium glucose co-transporters have shown proven benefit in diabetic kidney disease regression recently. Other potential targets for slowing the decline in diabetic kidney disease are transforming growth factor beta, endothelin antagonist, protein kinase C inhibitors, advanced glycation end product inhibition, Janus kinase-signal transducer and activator of transcription pathway inhibition, phosphodiesterase 3 or 5 inhibitors, and Rho kinase inhibitor. These targets are at various trial phases and so far, show promising results.